Medical Researches
Possibly Effective
Based on 15 Researches
We aimed to explore how selenium (Se) and zinc (Zn) levels affect the survival of men diagnosed with prostate cancer. In a study conducted in Poland from 2009 to 2015, we enrolled 338 prostate cancer patients and measured their serum levels of these micronutrients before they started any treatment.
By categorizing participants into quartiles based on their Se and Zn levels, we utilized Cox regression to evaluate the relationship between these levels and patient survival. Our findings revealed a notable interaction between selenium and zinc, suggesting that higher combined levels of these micronutrients correlate with increased survival rates in prostate cancer patients.
Specifically, patients in the highest quartile of both Se and Zn showed a remarkably high hazard ratio (HR = 20.9) compared to those in the lowest quartile. However, it’s important to note that while the interaction is significant, our study does not isolate the effects of selenium from zinc alone. Therefore, further research is warranted to better understand optimal selenium and zinc levels for different populations and how they might contribute to prostate cancer outcomes.
Read More
Selenium's potential in prostate cancerEnhancing Radiotherapy Sensitivity in Prostate Cancer with Lentinan-Functionalized Selenium Nanoparticles: Mechanistic Insights and Therapeutic Potential.
Moderate impact on treatment assessment
We sought to understand how selenium, specifically in the form of lentinan-functionalized selenium nanoparticles (LET-SeNPs), can improve radiotherapy outcomes for prostate cancer. Our investigation showed that when these nanoparticles were combined with X-ray therapy, they significantly hampered the growth of prostate cancer cells and their ability to form colonies. This effect was greater than either treatment alone.
The mechanism behind this enhanced sensitivity involved a complex interplay of cellular pathways. We observed that LET-SeNPs helped induce more robust apoptosis, or programmed cell death, by targeting various signaling routes in the cancer cells, such as the p53, MAPK, and AKT pathways. Moreover, they elevated levels of reactive oxygen species (ROS), which are known to promote apoptosis, while also decreasing the expression of Thioredoxin reductase, an enzyme that aids in DNA repair.
In animal models, the combination therapy proved effective in slowing down tumor growth, reinforcing our findings from the lab. These results suggest that using LET-SeNPs alongside X-ray therapy could potentially transform prostate cancer treatment, enhancing its effectiveness while possibly reducing side effects. Overall, we believe that selenium-modified nanoparticles hold significant promise for advancing cancer therapies.
Read More
Prodrug enhances prostate cancer therapyA novel selenium analog of HDACi-based twin drug induces apoptosis and cell cycle arrest via CDC25A to improve prostate cancer therapy.
Highly relevant to prostate cancer research
We explored an innovative approach to treating prostate cancer by developing a unique prodrug that combines a potent HDAC inhibitor with selenium. This new compound, known as SeSA-DCA, was designed to effectively target cancer cells while minimizing side effects.
The study assessed how SeSA-DCA works in the body and its impact on various prostate cancer cell lines. We observed that this compound not only inhibited cancer cell growth but also prompted cell death and reduced metastasis significantly. Our animal studies revealed that SeSA-DCA led to notable tumor shrinkage without causing serious toxicity, outperforming even the standard treatment of docetaxel.
Additionally, we found that SeSA-DCA was stable in the body's environment and broke down rapidly in the tumor area, releasing its active components. This dual-action mechanism makes SeSA-DCA a promising candidate for prostate cancer therapy, potentially improving outcomes for patients while offering a safer alternative to traditional treatments. Overall, our findings suggest that selenium combined with HDAC inhibition can play a crucial role in advancing prostate cancer treatment strategies.
Read More
Selenium's role in prostate cancerEffects of natural extract interventions in prostate cancer: A systematic review and network meta-analysis.
Effectiveness tied to silybin
We conducted a systematic exploration of natural extracts, with a particular focus on selenium, and its role in managing prostate cancer. The available evidence includes findings from various studies, including our analysis, which assessed the effectiveness of selenium alone and in combination with other extracts, such as silybin.
While selenium was noted in our findings, we found that its effectiveness is not straightforward. Specifically, the interaction between selenium and silybin complicated our ability to isolate the impact of selenium on its own. Thus, it became clear that, although some benefits arise from its combined use, we couldn’t definitively conclude that selenium alone delivers significant advantages for prostate cancer treatment.
Overall, the insights from our network meta-analysis suggest that while silybin and selenium together show promise, we need more studies to establish the detailed benefits and safety of selenium as a standalone treatment for prostate cancer. Those considering natural extract options should proceed with caution, keeping in mind the current limitations in evidence.
Read More
Targeted selenium treatment effectiveTargeted anti-tumor synergistic effects of Myc decoy oligodeoxynucleotides-loaded selenium nanostructure combined with chemoradiotherapy on LNCaP prostate cancer cells.
Study relevant to prostate cancer treatment
We investigated how selenium, combined with chemoradiotherapy, could target and treat prostate cancer, specifically in the LNCaP cell line. The study employed a sophisticated design involving methotrexate-selenium nanostructures loaded with Myc decoy oligodeoxynucleotides. This innovative approach aimed to enhance treatment effectiveness when paired with X-irradiation.
Throughout our experiments, we observed that these targeted nanostructures showcased promising characteristics. The selenium nanoparticles displayed a size of around 40 nanometers and a suitable negative charge, indicating a well-structured composite. Notably, they demonstrated hemocompatibility, meaning they are likely safe when interacting with blood cells at lower concentrations.
The results were encouraging: the combination therapy led to significant cell growth inhibition and about 57% apoptosis in the cancer cells. We also noted a substantial cell cycle arrest in the G2/M phase and a migration inhibition of up to 90%. These findings suggest that selenium, when used as part of a carefully designed nanostructure, can enhance the effectiveness of therapies against prostate cancer.
Read More
User Reviews
Selenium is an essential supplement for preventing cancer. To maintain my health and reduce tumour risks, I believe this supplement is crucial.
I've taken selenium regularly, which has significantly improved my metabolism and energy levels after dealing with hypothyroidism and related issues. It’s been life-changing and essential for my health.
After my early bladder cancer operation nearly ten years ago, I take selenium for prevention and follow a low-carb diet. The capsule size is just right and easy to swallow.
High selenium levels can protect against prostate cancer and cardiovascular diseases. I find it excellent for improving immunity and memory, with added benefits for asthma. I recommend it, especially with iodine.
This supplement has been beneficial in helping me cope with breast cancer.